Nice article. Thanks Yahoo, but could ya name a few names next time. Sounds like us. Not MITI's antibody method but directly modifying the T-cells themselves. From the article In this issue of the Journal, Porter and colleagues5 describe a heavily pretreated patient with chronic lymphocytic leukemia (CLL) who had a complete remission associated with the tumor lysis syndrome after adoptive immunotherapy with second-generation anti-CD19 chimeric antigen receptor–modified T cells. Four days after receiving chemotherapy with pentostatin and cyclophosphamide for depletion of lymphocytes, the patient received 1.42×107 transduced T cells over 3 days with no additional cytokines. Unselected peripheral-blood T cells were infected with a self-inactivating lentiviral vector carrying genes for the chimeric antigen receptor. These genes included the single-chain Fv from the hypervariable region of a human CD19-specific murine antibody, a hinge region, and human 4-1BB and CD3-zeta signaling domains. CD19 is the target of MT103